Is it true that patients may get worse during the initial weeks of treatment?
TRELSTAR may cause an initial temporary surge in testosterone levels, which can worsen symptoms of prostate cancer during the first few weeks of treatment. This worsening of symptoms is referred to as “clinical flare.” Patients may experience worsening of bone pain, neuropathy, blood in the urine, or obstruction of the bladder and/or urethra. These symptoms may disappear with continued therapy. Although not indicated for use with TRELSTAR, antiandrogens, such as flutamide or bicalutamide, are commonly administered with LHRH agonists to reduce clinical flare in advanced prostate cancer patients.
